BioPorto DiagnosticsA/S

BioPorto Diagnostics A/S is an in vitro diagnostics company that provides healthcare professionals in clinical and research institutions with a range of diagnostic tests and antibodies. BioPorto Diagnostics A/S’s pioneering portfolio includes tests for underserved disease states, such as NGAL for acute kidney injury. BioPorto Diagnostics A/S sells its products in more than 80 countries through various sales channels and partners. BioPorto is headquartered in Copenhagen, Denmark, and is listed on the Nasdaq Copenhagen Stock Exchange.